The groundbreaking success of the copyright undeniably reshaped the medication landscape, but investing in companies strongly reliant on generic versions presents a complex picture. Despite early earnings were substantial, the end of patents and the emergence of cheaper alternatives have diminished sales. Therefore, a thorough evaluation of current